Literature DB >> 17346312

Specific interaction of HeLa cell proteins with coxsackievirus B3 3'UTR: La autoantigen binds the 3' and 5'UTR independently of the poly(A) tail.

Paul Cheung1, Travis Lim, Jane Yuan, Mary Zhang, David Chau, Bruce McManus, Decheng Yang.   

Abstract

Coxsackievirus B3 (CVB3) is a positive, single-stranded RNA virus. The secondary structure of the 3' untranslated region (3'UTR) of CVB3 RNA consists of three stem-loops and is followed by a poly(A) tail sequence. These stem-loop structures have been suggested to participate in the regulation of viral replication through interaction with cellular proteins that are yet to be identified. In this study, by competitive UV cross-linking using mutated 3'UTR probes we have demonstrated that the poly(A) tail is essential for promoting HeLa cell protein interactions with the 3'UTR because deletion of this sequence abolished most of the protein interactions. Unexpectedly, mutations that disrupted the tertiary loop-loop interactions without affecting the stem-loops did not apparently affect these protein interactions, indicating that secondary structure rather than the high-order structure may play a major role in recruiting these RNA binding proteins. Among the observed 3'UTR RNA binding proteins, we have confirmed a 52 kDa protein as the human La autoantigen by using purified recombinant protein and a polyclonal La antibody. This protein can interact with both the 3' and 5'UTRs independently of the poly(A) tail. Further analysis by two-stage UV cross-linking, we found that the 3' and 5'UTR sequences may share the same binding site on the La protein.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17346312     DOI: 10.1111/j.1462-5822.2007.00904.x

Source DB:  PubMed          Journal:  Cell Microbiol        ISSN: 1462-5814            Impact factor:   3.715


  8 in total

Review 1.  Role of RNA structure motifs in IRES-dependent translation initiation of the coxsackievirus B3: new insights for developing live-attenuated strains for vaccines and gene therapy.

Authors:  Amira Souii; Manel Ben M'hadheb-Gharbi; Jawhar Gharbi
Journal:  Mol Biotechnol       Date:  2013-10       Impact factor: 2.695

2.  Cellular Proteins Act as Bridge Between 5' and 3' Ends of the Coxsackievirus B3 Mediating Genome Circularization During RNA Translation.

Authors:  Amira Souii; Manel Ben M'hadheb-Gharbi; Jawhar Gharbi
Journal:  Curr Microbiol       Date:  2015-07-03       Impact factor: 2.188

3.  Molecular Analysis of RNA-RNA Interactions between 5' and 3' Untranslated Regions during the Initiation of Translation of a Cardiovirulent and a Live-Attenuated Coxsackievirus B3 Strains.

Authors:  Amira Souii; Jawhar Gharbi; Manel Ben M'hadheb-Gharbi
Journal:  Int J Mol Sci       Date:  2013-02-25       Impact factor: 5.923

4.  Targeted delivery of mutant tolerant anti-coxsackievirus artificial microRNAs using folate conjugated bacteriophage Phi29 pRNA.

Authors:  Xin Ye; Zhen Liu; Maged Gomaa Hemida; Decheng Yang
Journal:  PLoS One       Date:  2011-06-15       Impact factor: 3.240

Review 5.  RNA-Binding Proteins as Regulators of Internal Initiation of Viral mRNA Translation.

Authors:  Brenda López-Ulloa; Yazmín Fuentes; Magdalena S Pizarro-Ortega; Marcelo López-Lastra
Journal:  Viruses       Date:  2022-01-19       Impact factor: 5.048

Review 6.  Viral and host proteins involved in picornavirus life cycle.

Authors:  Jing-Yi Lin; Tzu-Chun Chen; Kuo-Feng Weng; Shih-Cheng Chang; Li-Lien Chen; Shin-Ru Shih
Journal:  J Biomed Sci       Date:  2009-11-20       Impact factor: 8.410

Review 7.  Linking Α to Ω: diverse and dynamic RNA-based mechanisms to regulate gene expression by 5'-to-3' communication.

Authors:  Megan E Filbin; Jeffrey S Kieft
Journal:  F1000Res       Date:  2016-08-19

Review 8.  Structures and Functions of Viral 5' Non-Coding Genomic RNA Domain-I in Group-B Enterovirus Infections.

Authors:  Marie Glenet; Laetitia Heng; Domitille Callon; Anne-Laure Lebreil; Paul-Antoine Gretteau; Yohan Nguyen; Fatma Berri; Laurent Andreoletti
Journal:  Viruses       Date:  2020-08-21       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.